Over in Copenhagan, shares in drugmaker Zealand Pharma are down 25% after trial data showed its injectable obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.
Late-stage data from two studies of the drug, presented last weekend at a medical conference, showed that nearly one in four patients taking the highest 6-milligram dose of survodutide stopped treatment due to side effects, with about one in five dropping out specifically because of gastrointestinal problems.
